VOR (Vor Biopharma) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


VOR Vor Biopharma Inc VOR
32 GF Score
Price $19.14
! 3 Warning Signs
View Full Analysis

What is Vor Biopharma ROE % Adjusted to Book Value?

Vor Biopharma VOR -3.09% 32 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates VOR with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Vor Biopharma's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Vor Biopharma's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Vor Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Vor Biopharma ROE % Adjusted to Book Value Related Terms

Vor Biopharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Vor Biopharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vor Biopharma ROE % Adjusted to Book Value Chart

Vor Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -26.05 -22.54 -58.16 -66.10 0.00

Vor Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -117.43 0.00 0.00 Negative Equity 0.00

VOR vs ODTX, ANNX, ABUS: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Vor Biopharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vor Biopharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vor Biopharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vor Biopharma's ROE % Adjusted to Book Value falls into.


VOR
32GF Score
Vor Biopharma Inc VOR
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vor Biopharma ROE % Adjusted to Book Value Calculation

Vor Biopharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Vor Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Vor Biopharma (VOR) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vor Biopharma and its competitors.
Is Vor Biopharma's ROE % Adjusted to Book Value too high?
Vor Biopharma's current ROE % Adjusted to Book Value is 0.00%. Overall, Vor Biopharma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Vor Biopharma's ROE % Adjusted to Book Value compare to ODTX and ANNX?
Vor Biopharma's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vor Biopharma and its competitors. Vor Biopharma's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vor Biopharma stock overvalued right now?
Vor Biopharma (VOR) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Vor Biopharma's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vor Biopharma (VOR), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vor Biopharma Business Description

Address 500 Boylston Street, Suite 1350, Boston, MA, USA, 02116
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
32GF Score

Get the complete analysis for VOR

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.14
Price